Evidence map›Paper›PMID 41328628›Full record

SynthesisJournal of comparative effectiveness research2026

Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid-beta drugs in Alzheimer's disease: a Bayesian meta-analysis.

Sa Ren, Janharpreet Singh, Sandro Gsteiger, Christopher Cogley, Ben Reed, Keith R Abrams, Dalia Dawoud, Rhiannon K Owen, Paul Tappenden, Terrence J Quinn and 1 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of comparative effectiveness research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sa RenSheffield Centre for Health & Related Research, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.ORCID 0000-0001-9040-249X
Janharpreet SinghBiostatistics Research Group, Division of Public Health & Epidemiology, School of Medicine, University of Leicester, Leicester, UK.
Sandro GsteigerF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Christopher CogleyDivision of Public Health & Epidemiology, School of Medicine, University of Leicester, Leicester, UK.
Ben ReedDivision of Public Health & Epidemiology, School of Medicine, University of Leicester, Leicester, UK.
Keith R AbramsDepartment of Statistics, University of Warwick, Coventry, UK.
Dalia DawoudNational Institute for Health & Care Excellence, London, UK.
Rhiannon K OwenPopulation Data Science, Swansea University Medical School, Swansea University, Swansea, UK.
Paul TappendenSheffield Centre for Health & Related Research, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.
Terrence J QuinnSchool of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK.
Sylwia BujkiewiczBiostatistics Research Group, Division of Public Health & Epidemiology, School of Medicine, University of Leicester, Leicester, UK.ORCID 0000-0002-3003-9403

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBayes TheoremBiomarkersHumansRandomized Controlled Trials as TopicaducanumabAmyloid beta-PeptidesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkersAlzheimer's diseaseamyloid-betaclinical outcomesmeta-analysissurrogate endpoint

Identifiers

PMID41328628
PMCPMC12711098

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.